<DOC>
	<DOC>NCT01718678</DOC>
	<brief_summary>The purpose of this study was to evaluate the efficacy and safety of Melatonin in treatment of fatigue and Quality of Life of MS patients.</brief_summary>
	<brief_title>Effect of Melatonin on Multiple Sclerosis Related Fatigue</brief_title>
	<detailed_description>Multiple Sclerosis (MS) is one of the most common non-traumatic causes of disability in the world. It is a chronic inflammatory and demyelinating disorder of the Central Nervous System (CNS) which affects individuals in the productive ages and causes a large burden for years to come. Fatigue is a common complaint and one of the least understood symptoms of MS</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>1. definite diagnosis of relapsingremitting MS (RRMS) by the MacDonald criteria 2. a baseline of Expanded Disability Status Score (EDSS)of less than 5.0 3. aged between 18 and 55 years of either sex 4. treated with one type of interferon beta1a (IFNB1a); 5. signed an informed consent 1. clinical relapsing of MS during past 30 days; 2. use of melatonin and warfarin within 30 days prior to participation; 3. concomitant use of betablockers, antidiabetic agents, antiplatelet agents, NSAIDS, aspirin ; 4. working more than one nighttime shift per month; 5. Pregnancy or lactation; 6. history of a chronic hematological, cardiac, hepatic, renal or thyroid disorders ; 7. failure to adhere to the study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Melatonin</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Quality of life</keyword>
</DOC>